AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36782227 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% fraction of inspired oxygen (FiO2)
Number of subjects: 193
Study 36782227 — intervention group
Group type: COMPARATOR
Intervention: 28% fraction of inspired oxygen (FiO2)
Number of subjects: 193
Study 36782282 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography monitoring of bone mineral density (BMD)
Number of subjects: 60
Study 36782282 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a personal factor
Number of subjects: 60
Study 36782282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall BMD change across different foot bones
Number of subjects: 60
Study 36782297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 1595
Study 36782297 — intervention group
Group type: COMPARATOR
Intervention: Preconception
Number of subjects: 1595
Study 36782301 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCEPT decision intervention (ADI)
Number of subjects: 24
Study 36782325 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (1500 mg once weekly for 8 weeks)
Number of subjects: 68
Study 36782325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 36782325 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 68
Study 36782326 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ILA
Number of subjects: 1699
Study 36785526 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Number of subjects: 282
Study 36785526 — intervention group
Group type: COMPARATOR
Intervention: 14 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Number of subjects: 282
Study 36785834 — intervention group
Group type: EXPERIMENTAL
Intervention: DeepInteg (multi-task deep learning tool)
Number of subjects: 1700
Study 36785850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+1 PCV10 schedule (2,3,4,9 months)
Number of subjects: 1049
Study 36785850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+0 PCV10 schedule (2,3,4 months)
Number of subjects: 1049
Study 36785850 — intervention group
Group type: EXPERIMENTAL
Intervention: 2+1 PCV10 schedule (2,4,9.5 months)
Number of subjects: 1049
Study 36785850 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose PCV10 schedule (2,6 months)
Number of subjects: 1049
Study 36785850 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infant doses of PCV)
Number of subjects: 1049
Study 36785996 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 494
Study 36785996 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 494
Study 36785996 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 494
Study 36786049 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing infusion set every 0-4 days
Number of subjects: 770
Study 36786049 — intervention group
Group type: EXPERIMENTAL
Intervention: Never/rarely missing a bolus
Number of subjects: 770
Study 36786049 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing insulin 10-15 min before meal
Number of subjects: 770
Study 36786049 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjusting pump settings
Number of subjects: 770
Study 36786049 — intervention group
Group type: COMPARATOR
Intervention: Health care professionals doing all adjustments
Number of subjects: 770
Study 36786053 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-73763989 (200 mg, single subcutaneous dose)
Number of subjects: 0
Study 36786053 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-56136379 (250 mg, oral, single dose)
Number of subjects: 0
Study 36786053 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-73763989 and JNJ-56136379
Number of subjects: 0
Study 36786053 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Number of subjects: 0
Study 36786322 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-overuse headache patients
Number of subjects: 120
Study 36786322 — intervention group
Group type: COMPARATOR
Intervention: Controls (episodic migraine patients and healthy controls)
Number of subjects: 120
Study 36786394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of M1
Number of subjects: 35
Study 36786565 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation (ReActiv8)
Number of subjects: 146
Study 36787013 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical management plus ReActiv8® restorative neurostimulation therapy
Number of subjects: 0
Study 36787013 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study 36787089 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB062079 15 mg twice daily
Number of subjects: 23
Study 36787089 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB062079 10 mg once daily
Number of subjects: 23
Study 36787089 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB062079
Number of subjects: 23
Study 36787124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diuretics with varying pharmacological targets for diuretic resistance and sodium avidity
Number of subjects: 0
Study 36787124 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive decongestion methods including ultrafiltration or kidney replacement therapy (KRT) such as peritoneal dialysis
Number of subjects: 0
Study 36787124 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for increasing forward perfusion in low cardiac output and cardiogenic shock
Number of subjects: 0
Study 36787125 — intervention group
Group type: COMPARATOR
Intervention: Assistance
Number of subjects: 4517
Study 36787125 — intervention group
Group type: COMPARATOR
Intervention: Assistance with Surveillance
Number of subjects: 4517
Study 36787125 — intervention group
Group type: COMPARATOR
Intervention: Collaborative
Number of subjects: 4517
Study 36787125 — intervention group
Group type: COMPARATOR
Intervention: Collaborative with Surveillance
Number of subjects: 4517
Study 36787165 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-supported patient navigation for 12 months
Number of subjects: 450
Study 36787165 — intervention group
Group type: COMPARATOR
Intervention: Standard of care patient support
Number of subjects: 450
Study 36787172 — intervention group
Group type: EXPERIMENTAL
Intervention: SiS smartphone app
Number of subjects: 225
Study 36787172 — intervention group
Group type: COMPARATOR
Intervention: QuitGuide smartphone app
Number of subjects: 225
Study 36787172 — intervention group
Group type: COMPARATOR
Intervention: Clearing the Air brochure
Number of subjects: 225
Study 36787181 — intervention group
Group type: EXPERIMENTAL
Intervention: REsOluTioN program (Resilience Enhancement Online Training for Nurses)
Number of subjects: 93
Study 36787181 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 93
Study 36787235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based music therapy intervention (4 sessions, 45 minutes each over 12 weeks)
Number of subjects: 31
Study 36787249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic vaccine
Number of subjects: 105
Study 36787249 — intervention group
Group type: COMPARATOR
Intervention: CON-S vaccine
Number of subjects: 105
Study 36787249 — intervention group
Group type: COMPARATOR
Intervention: Nat-B vaccine
Number of subjects: 105
Study 36787296 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based SAMBA II assay
Number of subjects: 390
Study 36787296 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) VL monitoring at provincial referral laboratory (PRL)
Number of subjects: 390
Study 36787296 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) VL monitoring at PRL
Number of subjects: 390
Study 36787296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 390
Study 36787305 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day orally for 7 days
Number of subjects: 40
Study 36787305 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 40
Study 36787455 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36787512 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based tailored risk counseling and navigation intervention (TCN)
Number of subjects: 0
Study 36787512 — intervention group
Group type: COMPARATOR
Intervention: Mailed targeted print education (TP)
Number of subjects: 0
Study 36787512 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 36787524 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS-TA (Xipere®; Bausch + Lomb) administered via the SCS Microinjector®
Number of subjects: 0
Study 36787524 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS-TA (Xipere®; Bausch + Lomb)
Number of subjects: 0
Study 36787525 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol cream 50 μg
Number of subjects: 50
Study 36787525 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol cream 100 μg
Number of subjects: 50
Study 36787525 — intervention group
Group type: COMPARATOR
Intervention: Silicone lubricant (control)
Number of subjects: 50
Study 36787525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined (estradiol and silicone lubricant)
Number of subjects: 50
Study 36787527 — intervention group
Group type: EXPERIMENTAL
Intervention: German Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire
Number of subjects: 121
Study 36787645 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36787802 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months post COVID-19
Number of subjects: 536
Study 36787802 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months post COVID-19
Number of subjects: 536
Study 36787802 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment
Number of subjects: 536
Study 36787836 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-granular (NG)-LNPCPs
Number of subjects: 3381
Study 36787836 — intervention group
Group type: COMPARATOR
Intervention: Solitary LNPCPs
Number of subjects: 3381
Study 36787836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant LNPCPs in patients with multiple LNPCPs
Number of subjects: 3381
Study 36787969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery compliance (PAC)
Number of subjects: 616
Study 36787969 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-compliance (RC) time
Number of subjects: 616
Study 36787969 — intervention group
Group type: EXPERIMENTAL
Intervention: RC time in CTD-PAH
Number of subjects: 616
Study 36787969 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC
Number of subjects: 616
Study 36787971 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS calculator
Number of subjects: 1830
Study 36787971 — intervention group
Group type: COMPARATOR
Intervention: Dutch guideline
Number of subjects: 1830
Study 36787974 — intervention group
Group type: EXPERIMENTAL
Intervention: High nCPAP (positive end-expiratory pressure 9-15 cmH2O)
Number of subjects: 0
Study 36787974 — intervention group
Group type: COMPARATOR
Intervention: NIPPV (target mean Paw 9-15 cmH2O)
Number of subjects: 0
Study 36787974 — intervention group
Group type: EXPERIMENTAL
Intervention: High nCPAP or NIPPV
Number of subjects: 0
Study 36788015 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (includes 4-Hydroxy-3-methoxyphenylglycol sulfate, galacturonic acid, hexanoylcarnitine, and age)
Number of subjects: 1682
Study 36788015 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (includes 4-Hydroxy-3-methoxyphenylglycol sulfate, hexanoylcarnitine, bilirubin, INR, and age)
Number of subjects: 1682
Study 36788015 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1
Number of subjects: 1682
Study 36788015 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2
Number of subjects: 1682
Study 36788015 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including metabolites (CLIF-C MET)
Number of subjects: 1682
Study 36788081 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term preoperative endocrine therapy (pET; tamoxifen or aromatase inhibitor)
Number of subjects: 364
Study 36788198 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 30
Study 36788198 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight blade videolaryngoscopy
Number of subjects: 30
Study 36788198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperangulated videolaryngoscopy
Number of subjects: 30
Study 36788198 — intervention group
Group type: COMPARATOR
Intervention: Videolaryngoscopy (both types)
Number of subjects: 30
Study 36788215 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved water, sanitation and hygiene (WASH) and infant and young child feeding (IYCF) interventions
Number of subjects: 335
Study 36788215 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 335
Study 36788215 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional metagenomic features
Number of subjects: 335
Study 36788482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency training (3 times a week for 12 weeks)
Number of subjects: 89
Study 36788482 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency training (1 time a week for 12 weeks)
Number of subjects: 89
Study 36788482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HF and LF groups
Number of subjects: 89
Study 36788511 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TAC 0.1% patch twice daily
Number of subjects: 30
Study 36788511 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TAC 0.1% gel
Number of subjects: 30
Study 36788511 — intervention group
Group type: COMPARATOR
Intervention: Topical TRI 0.1% gel four times daily
Number of subjects: 30
Study 36788520 — intervention group
Group type: EXPERIMENTAL
Intervention: AstroRx® (100 × 10^6 cells)
Number of subjects: 5
Study 36788619 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 32
Study 36788619 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study 36788652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional Lens Index (DLI)
Number of subjects: 106
Study 36788652 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCS III
Number of subjects: 106
Study 36789426 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention targeting distress and anxiety symptoms
Number of subjects: 0
Study 36789426 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36789481 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 999
Study 36789481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 999
Study 36789481 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 999
Study 36789515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 751
Study 36789515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study 36789515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0 mg/day
Number of subjects: 751
Study 36789515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day and 3.0 mg/day
Number of subjects: 751
Study 36789577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexuprazan 20 mg once a day (q.d.)
Number of subjects: 327
Study 36789577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexuprazan 10 mg twice a day (b.i.d.)
Number of subjects: 327
Study 36789577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 36789614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant
Number of subjects: 306
Study 36789614 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agent
Number of subjects: 306
Study 36789614 — intervention group
Group type: COMPARATOR
Intervention: Hospitalisation
Number of subjects: 306
Study 36789614 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 306
Study 36789614 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin level
Number of subjects: 306
Study 36789614 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant vs. antiplatelet agent
Number of subjects: 306
Study 36789614 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic events
Number of subjects: 306
Study 36789614 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 306
Study 36789773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 4168
Study 36789773 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-aspirin
Number of subjects: 4168
Study 36789835 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high burden PVC group (≥1000/day)
Number of subjects: 16030
Study 36789835 — intervention group
Group type: COMPARATOR
Intervention: Low burden PVC group (<1000/day)
Number of subjects: 16030
Study 36789931 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miR-128-1-5p levels
Number of subjects: 495
Study 36789941 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic vegetable intake
Number of subjects: 3229
Study 36789941 — intervention group
Group type: EXPERIMENTAL
Intervention: Scallion intake
Number of subjects: 3229
Study 36789941 — intervention group
Group type: EXPERIMENTAL
Intervention: Total allium vegetable intake
Number of subjects: 3229
Study 36789941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prevalence of dysplasia or GC
Number of subjects: 3229
Study 36789945 — intervention group
Group type: EXPERIMENTAL
Intervention: FeFum+GOS (5.0 mg iron with 3.0 g GOS)
Number of subjects: 55
Study 36789945 — intervention group
Group type: EXPERIMENTAL
Intervention: FeFum+HMO (5.0 mg iron with 3.0 g HMO)
Number of subjects: 55
Study 36789945 — intervention group
Group type: COMPARATOR
Intervention: FeFum (5.0 mg iron without GOS or HMO)
Number of subjects: 55
Study 36789945 — intervention group
Group type: EXPERIMENTAL
Intervention: FeFum+GOS
Number of subjects: 55
Study 36789945 — intervention group
Group type: EXPERIMENTAL
Intervention: FeFum+HMO
Number of subjects: 55
Study 36789947 — intervention group
Group type: EXPERIMENTAL
Intervention: Short breastfeeding (≤4 months)
Number of subjects: 839
Study 36789947 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complementary feeding (≤4 months)
Number of subjects: 839
Study 36789947 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CF and short BF
Number of subjects: 839
Study 36789947 — intervention group
Group type: COMPARATOR
Intervention: Early CF-long BF
Number of subjects: 839
Study 36789976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion-to-fat ratio measured by shear wave elastography
Number of subjects: 1288
Study 36789976 — intervention group
Group type: COMPARATOR
Intervention: Conventional B-mode ultrasound
Number of subjects: 1288
Study 36790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily (induction)
Number of subjects: 0
Study 36790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily (maintenance)
Number of subjects: 0
Study 36790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily (maintenance)
Number of subjects: 0
Study 36790041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (induction and maintenance)
Number of subjects: 0
Study 36790138 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol supplementation
Number of subjects: 1319
Study 36790141 — intervention group
Group type: EXPERIMENTAL
Intervention: DM1
Number of subjects: 185
Study 36790141 — intervention group
Group type: EXPERIMENTAL
Intervention: DM2
Number of subjects: 185
Study 36790141 — intervention group
Group type: COMPARATOR
Intervention: Non-DM muscular dystrophy cohort
Number of subjects: 185
Study 36790337 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 57
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 791
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity (1 child)
Number of subjects: 791
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity (≥ 2 children)
Number of subjects: 791
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of total meat (≥ 108.57 g/day)
Number of subjects: 791
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of red/processed meat (≥ 74.29 g/day)
Number of subjects: 791
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of protein (≥ 65.05 g/day)
Number of subjects: 791
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of dietary iron (≥ 8.58 mg/day)
Number of subjects: 791
Study 36790457 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 791
Study 36790588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of GFAP, NSE, IFN-γ, TNF-α, IL-2, IL-12p70, IL-4, IL-10, and IL-13
Number of subjects: 15
Study 36790588 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood (PB) concentrations of GFAP and IFN-γ
Number of subjects: 15
Study 36790588 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) and peripheral blood (PB) biomarker concentrations
Number of subjects: 15
Study 36790596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg metformin with 10 mg baxdrostat
Number of subjects: 27
Study 36790596 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg metformin alone
Number of subjects: 27
Study 36790672 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level red-light (RLRL) therapy
Number of subjects: 264
Study 36790672 — intervention group
Group type: COMPARATOR
Intervention: Single vision spectacle (SVS)
Number of subjects: 264
Study 36790808 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Proximal Gastrectomy with Double-Tract Reconstruction (LPG-DTR)
Number of subjects: 138
Study 36790808 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Total Gastrectomy (LTG)
Number of subjects: 138
Study 36790808 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG-DTR
Number of subjects: 138
Study 36790808 — intervention group
Group type: COMPARATOR
Intervention: LTG
Number of subjects: 138